Argenx
ARGX
#534
Rank
$38.14 B
Marketcap
$623.82
Share price
-0.35%
Change (1 day)
76.16%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2024 (TTM): $1.85 Billion USD

According to Argenx 's latest financial reports the company's current revenue (TTM ) is $1.85 Billion USD. In 2023 the company made a revenue of $1.22 Billion USD an increase over the revenue in the year 2022 that were of $0.41 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) $1.85 B51.57%
2023 $1.22 B198.56%
2022 $0.41 B
2019 $87.64 M200.86%
2018 $29.13 M-42.03%
2017 $50.25 M193.93%
2016 $17.09 M105.69%
2015 $8.31 M43.78%
2014 $5.78 M16.68%
2013 $4.95 M